Antiandrogens [2,6] such as cyproterone acetate, nilutamide, flutamide, bicalutamide etc. are then used to abolish androgenic effects on prostate cancer cells, by competing with androgen for AR binding to consequently slow down or inhibit their growth. Here, AR is linked to prostate carcinoma.